Status:
COMPLETED
Barrett's Esophagus - 315 - 3 Way Cross-Over
Lead Sponsor:
AstraZeneca
Conditions:
Barrett's Esophagus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole ...
Eligibility Criteria
Inclusion
- Must have a previously established, biopsy-proven diagnosis of Barrett's esophagus with segment length greater than 3cm, with no dysplasia or adenocarcinoma within the previous 12 months
Exclusion
- A history of esophageal, gastric, or duodenal surgery, including anti-reflux surgery or endoscopic anti-reflux procedures, except for simple closure of a gastric or duodenal ulcer.
- History of various gastrointestinal diseases - please see investigator for full list.
- Evidence of any malignant disease in the last 5 years, except minor superficial skin disease.
- Unstable diabetes mellitus. Stable on a controlled diet, oral agents or insulin are acceptable.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2003
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00637559
Start Date
March 1 2002
End Date
April 1 2003
Last Update
January 25 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.